Article

Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer

Department of Obstetrics and Gynaecology, University of Helsinki, Helsinki, Uusimaa, Finland
JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 10/2011; 306(14):1557-65. DOI: 10.1001/jama.2011.1456
Source: PubMed

ABSTRACT

Attempts to determine the clinical significance of BRCA1/2 mutations in ovarian cancer have produced conflicting results.
To determine the relationships between BRCA1/2 deficiency (ie, mutation and promoter hypermethylation) and overall survival (OS), progression-free survival (PFS), chemotherapy response, and whole-exome mutation rate in ovarian cancer.
Observational study of multidimensional genomics and clinical data on 316 high-grade serous ovarian cancer cases that were made public between 2009 and 2010 via The Cancer Genome Atlas project.
OS and PFS rates (primary outcomes) and chemotherapy response (secondary outcome).
BRCA2 mutations (29 cases) were associated with significantly better OS (adjusted hazard ratio [HR], 0.33; 95% CI, 0.16-0.69; P = .003 and 5-year OS, 61% for BRCA2-mutated vs 25% for BRCA wild-type cases) and PFS (adjusted HR, 0.40; 95% CI, 0.22-0.74; P = .004 and 3-year PFS, 44% for BRCA2-mutated vs 16% for BRCA wild-type cases), whereas neither BRCA1 mutations (37 cases) nor BRCA1 methylation (33 cases) was associated with prognosis. Moreover, BRCA2 mutations were associated with a significantly higher primary chemotherapy sensitivity rate (100% for BRCA2-mutated vs 82% [P = .02] and 80% [P = .05] for BRCA wild-type and BRCA1-mutated cases, respectively) and longer platinum-free duration (median platinum-free duration, 18.0 months for BRCA2-mutated vs 11.7 [P = .02] and 12.5 [P = .04] months for BRCA wild-type and BRCA1-mutated cases, respectively). BRCA2-mutated, but not BRCA1-mutated cases, exhibited a "mutator phenotype" by containing significantly more mutations than BRCA wild-type cases across the whole exome (median mutation number per sample, 84 for BRCA2-mutated vs 52 for BRCA wild-type cases, false discovery rate <0.1).
Among women with high-grade serous ovarian cancer, BRCA2 mutation, but not BRCA1 deficiency, was associated with improved survival, improved chemotherapy response, and genome instability compared with BRCA wild-type.

Download full-text

Full-text

Available from: Ken Hess, Jul 22, 2014
  • Source
    • "Their results will enable comprehensive models of prion replication to be developed and will facilitate the investigation of novel therapeutic approaches. In the field of cancer research, notable studies include the research carried out by Oyama et al.[40]in which they identified the links that lead to the resistance or insensitivity to tamoxifen in breast cancer patients; Yang et al.[41]discovered that the BRCA2 mutation (a known risk-associated gene for breast cancer) is an independent predictor of improved survival rate and response to platinum-based chemotherapy. Finally, Clyde et al.[42]used dynamic systems modeling to examine the role of an inhibitor of the ataxia telangiectasia mutated gene in the DNA damageresponse network. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a complex, multifactorial disease that has reached global epidemic proportions. The challenge remains to fully identify its underlying molecular mechanisms that will enable development of accurate diagnostic tools and therapeutics. Conventional experimental approaches that target individual or small sets of genes or proteins may overlook important parts of the regulatory network, which limits the opportunity of identifying multitarget interventions. Our perspective is that a more complete insight into potential treatment options for AD will only be made possible through studying the disease as a system. We propose an integrative systems biology approach that we argue has been largely untapped in AD research. We present key publications to demonstrate the value of this approach and discuss the potential to intensify research efforts in AD through transdisciplinary collaboration. We highlight challenges and opportunities for significant breakthroughs that could be made if a systems biology approach is fully exploited.
    Full-text · Article · Dec 2015 · Alzheimer's and Dementia
  • Source
    • "The phenotype of BRCA-deficient ovarian cancers is of enhanced survival [20] [21] [22] [23], largely attributed to a better response to platinum chemotherapy. This phenotype of enhanced survival appears to also extend to ovarian cancers with deficiencies in other homologous recombination genes [24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Almost exactly twenty years after their discovery, the BRCA1 and BRCA2 genes have become the target of the first "personalized" therapy available for patients with ovarian cancer. In December 2014, a poly(ADP-ribose) polymerase (PARP) inhibitor was granted expedited approved by the United States Food and Drug Administration for use in advanced ovarian cancer patients with germline BRCA1/2 mutations who have received three or more prior lines of chemotherapy. This review article will discuss (1) the BRCA1 and BRCA2 genes within the larger context of homologous recombination deficiency; (2) the advances in our understanding of hereditary cancer risk and the dramatic shifts that have occurred in the genetic testing landscape since the landmark 2013 Supreme Court ruling invalidating patents on BRCA1 and BRCA2 genetic testing; and (3) the clinical trials leading to the approval of olaparib, the first in human PARP inhibitor. Copyright © 2015. Published by Elsevier Inc.
    Full-text · Article · Feb 2015 · Gynecologic Oncology
  • Source
    • "We then used drug-free survival analysis to evaluate the possibility of promoter methylation of lincRNAs as drug targets. The drug-free interval was defined as from the end of chemotherapeutic drug treatment to the date of progression or recurrence or last contact (censored) (56). XLOC_007617 was a lincRNA that showed positive correlation between its methylation and drug-free survival in UCEC (log-rank P = 0.013; Supplementary Figure S8). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite growing consensus that long intergenic non-coding ribonucleic acids (lincRNAs) are modulators of cancer, the knowledge about the deoxyribonucleic acid (DNA) methylation patterns of lincRNAs in cancers remains limited. In this study, we constructed DNA methylation profiles for 4629 tumors and 705 normal tissue samples from 20 different types of human cancer by reannotating data of DNA methylation arrays. We found that lincRNAs had different promoter methylation patterns in cancers. We classified 2461 lincRNAs into two categories and three subcategories, according to their promoter methylation patterns in tumors. LincRNAs with resistant methylation patterns in tumors had conserved transcriptional regulation regions and were ubiquitously expressed across normal tissues. By integrating cancer subtype data and patient clinical information, we identified lincRNAs with promoter methylation patterns that were associated with cancer status, subtype or prognosis for several cancers. Network analysis of aberrantly methylated lincRNAs in cancers showed that lincRNAs with aberrant methylation patterns might be involved in cancer development and progression. The methylated and demethylated lincRNAs identified in this study provide novel insights for developing cancer biomarkers and potential therapeutic targets.
    Full-text · Article · Jul 2014 · Nucleic Acids Research
Show more